ClinicalTrials.gg
RecruitingNCT05904548VISABL-AFLUpdated Nov 20, 2026

Atrial Flutter Ablation in the iCMR

An interventional study of RF Ablation in Atrial Flutter Typical, sponsored by Imricor Medical Systems. Recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Imricor Medical Systems · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Nov 20, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Atrial Flutter with a site in United States — 11 open to participants now, 14 under way, 1 of them phase 3. Atrial Flutter · United States.

Planned enrollment
39th of 55
91 · median 196
Started
2024
with 6 others
No phase
28 of 80
7 open now
Primary completion
2026-12
later than 5 of 13 live
Registered
68th of 80
by date

Among the 80 studies in Atrial Flutter with a site in United States, this one is the 39th largest by planned enrollment of the 55 interventional ones that give a count, is one of 7 that started in 2024, is one of 28 with no phase, reaches primary completion later than 5 of the 13 other live ones, and was the 68th registered.

Atrial Flutter

223 studies on the registry are indexed under Atrial Flutter; 51 are open to participants now.

Browse Atrial Flutter studies →

Open to participants now

11 of the 80 studies in Atrial Flutter with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Atrial Flutter studies recruiting now, 29 (83%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Atrial Flutter with a site in United States, or all of them as a file.
02

Study summary

The VISABL-AFL clinical investigation is a prospective, single-arm, multi-center, interventional, Investigational Device Exemption (IDE) trial. The primary objectives of VISABL-AFL are to assess the safety and efficacy of radiofrequency (RF) ablation of type-I atrial flutter performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.

03

Conditions studied

  • Atrial Flutter Typical

Browse trials for

Keywords

  • RF Ablation
  • interventional Cardiac Magnetic Resonance (iCMR)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient indicated for type I atrial flutter ablations with at least 1 documented episode of type I atrial flutter within 6 months (180 days) of enrollment
  • Patient 18 years and older

Exclusion criteria

Exclusion Criteria:

  • for MRI procedures
  • Patients who cannot have anti-arrhythmic drugs (class I or class III) prescribed for the treatment of type I atrial flutter stopped on the day of the procedure
  • Previous CTI ablation procedures
  • Myocardial infarction within 60 days of enrollment
  • Current unstable angina
  • Cardiac surgery within 90 days of enrollment
  • Any cerebral ischemic event (including ) within 6 months (180 days) of enrollment
  • Thrombocytosis or thrombocytopenia
  • Contraindication to anticoagulation therapy
  • Currently documented intracardiac thrombus or myxoma
  • Implantation of permanent leads of an implantable device in or through the right atrium within 90 days of enrollment
  • Prosthetic valve through which the catheter must pass
  • Interatrial baffle or patch through which the catheter must pass
  • Moderate or severe tricuspid valve regurgitation or stenosis
  • Uncompensated congestive heart failure
  • Active systemic infection
  • Pregnancy or if subject plans to become pregnant during the trial
  • Uncontrolled hyperthyroidism
  • Any other significant uncontrolled or unstable medical condition
  • Enrollment in any concurrent study without Imricor written approval
  • of less than or equal to 2 years (730 days) per physician opinion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (estimated)

Study arms

  • Experimental
    Vision-MR Atrial Flutter Ablation

    Type 1 Atrial Flutter ablation performed in the iCMR with the Vision-MR Ablation Catheter 2.0 and associated Advantage-MR EP recorder and stimulator system.

    Device: RF Ablation

Interventions

  • DeviceRF Ablation

    RF ablation for type I atrial flutter under iCMR guidance

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint: Bi-directional block confirmation

    Confirmation of bidirectional conduction block of the CTI with the Vision-MR Ablation Catheter 2.0 and Osypka HAT 500 RF generator \& irrigation pump.

    Time frame: Time of procedure, following delivery of last ablation energy delivery point

  2. Primary Safety Endpoint: Composite of serious cardiovascular adverse events

    A composite of the following serious adverse events as adjudicated by an independent clinical events committee: * Cardiac perforation/tamponade * Cerebrovascular accident (CVA) * Transient ischemic attack (TIA) * Complete heart block * Myocardial infarction * Pulmonary embolism * MR-related serious adverse events * Unanticipated device related serious adverse events * Death

    Time frame: 7-days post procedure

Secondary outcomes

  1. Chronic Efficacy Endpoint: Freedom from type 1 atrial flutter at 90 days

    The percent of subjects free of documented type I atrial flutter recurrence

    Time frame: 3 months (90 days)

  2. Chronic Safety Endpoint: all serious adverse event rate for duration of study

    Rate of Serious Adverse Events during the clinical investigation as adjudicated by an independent clinical events committee

    Time frame: 3 months (90 days)

07

Study locations

5 of 6 sites recruiting
  • Johns Hopkins University (JHU)
    Baltimore, Maryland 21218, United States
    Recruiting
    • Aravindan Kolandaivelu, MD · Principal investigator
  • University of Virginia (UVA)
    Charlottesville, Virginia 22903, United States
    Recruiting
    • Kenneth Bilchick, MD · Principal investigator
  • Virginia Commonwealth University
    Richmond, Virginia 23284, United States
    Recruiting
  • l'institut Cardiologique Paris Sud (ICPS)
    Massy, 91300, France
    Recruiting
    • Laurent Fiorina, MD · Principal investigator
  • Amsterdam University Medical Center (AUMC)
    Amsterdam, Netherlands
    Active, not recruiting

    Not enrolling at this site.

  • University Hospital of Vaud (CHUV)
    Lausanne, 1011, Switzerland
    Recruiting
    • Juerg Schwitter, MD · Principal investigator
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 55 interventional studies with no phase under Atrial Flutter, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2023
First posted
Jun 15, 2023
StartActual
Jun 20, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (2 now recruiting, 1 now active, not recruiting)
Show 3 sites
  • University of Virginia (UVA) · Charlottesville, United StatesNot yet recruiting→Recruiting
  • Virginia Commonwealth University · Richmond, United StatesNot yet recruiting→Recruiting
  • Amsterdam University Medical Center (AUMC) · Amsterdam, NetherlandsRecruiting→Active, not recruiting
across 2 updates, Oct 19, 2026 – Nov 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Amsterdam University Medical Center (AUMC) · Amsterdam, NetherlandsContact removed (no phone or email listed)
Nov 20, 2026
Show all 2 updates
  1. Nov 20, 2026
    Amsterdam University Medical Center (AUMC) is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Amsterdam University Medical Center (AUMC) · Amsterdam, NetherlandsContact removed (no phone or email listed)
    + 1 other change: verification date
  2. Oct 19, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • University of Virginia (UVA) · Charlottesville, United StatesNot yet recruiting→Recruiting
    • Virginia Commonwealth University · Richmond, United StatesNot yet recruiting→Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05904548
Lead sponsor
Imricor Medical Systems
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Jun 20, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 20, 2026

Study contacts

Kate Lindborg
Contact
kate.lindborg@imricor.com
952-818-8400
Jennifer Somerville
Contact
jennifer.somerville@imricor.com
952-594-4138
Kate Lindborg
study director · Imricor Medical Systems, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion